The Role of Leukocyte Immunoglobulin Receptor B2 Overexpression as a Novel Biomarker and Potential Therapeutic Agent for Colorectal Cancer

Abstract

There is an urgent need to identify screening markers and precise therapeutic targets for colorectal cancer (CRC), which has become the third most deadly malignancy in the world. In the past few decades, the medical field has implemented multiple levels of CRC screening tests, including fecal tests, endoscopic examinations, radiological examinations, and blood tests. Acute myeloid leukemia and non-small cell lung cancer have previously been shown to exhibit leukocyte immunoglobulin-like receptor B2 (LILRB2)-mediated immune evasion and tumor progression. CRC was identified as a characteristic protein by several researchers upon their research by LILRB2, but there is no clear relationship between LILRB2 expression and clinicopathological characteristics, internal mechanisms underlying CRC progression, or screening diagnostic effectiveness. Our hypothesis was that LILRB2 is highly expressed in CRC tissues, correlates with advanced stages and poor prognoses, and could be used as a screening biomarker and a therapeutic target. Despite this, there is still room for discussion regarding this research’s data processing and analysis.